Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2012

View Archived Issues

Promising nanoparticle-based dental treatment developed in Germany

Add-on apricoxib therapy may benefit subset of patients with pancreatic cancer

First HSP 90 inhibitor assessed in individuals with colorectal cancer

PI3K inhibitors active against gastrointestinal cancer cells

Ranbaxy Laboratories discloses novel 5-lipoxygenase inhibitors

Novel muscarinic acetylcholine M3 receptor antagonists presented

GlaxoSmithKline designs new bromodomain-containing protein inhibitors

Acura Pharmaceuticals provides Oxecta commercial update

Novel antiproliferative molecules patented at U.K. university

Belgian researchers disclose new protein kinase inhibitors

Aphios receives phase II SBIR grant to develop Alzheimer's disease therapy

Russian trial begins for Medistem's stem cell product for heart failure

Enlivex Therapeutics reports promising preliminary results in GVHD

Longitudinal data show applicability of florbetaben (18F) as a PET imaging agent in AD

NovaBay prepares to start phase IIb NVC-422 trial

Boehringer Ingelheim and Priaxon extend collaboration

Depomed starts new study of DM-1992

Almirall and BioFocus enter respiratory disease research alliance

Critical Outcome Technologies advances AML program

Johnson & Johnson highlights activities of fourth quarter 2011

Extended indication for Rebif approved in E.U.

Roche makes acquisition offer

NICE issues final guidance on Eliquis for VTE prevention in hip and knee surgery

Phase I/IIa trial launched of herbal product for Alzheimer's disease

Marina Biotech's START-FAP study advances to next stage

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...